IBOTTA INC-CL A (IBTA) Fundamental Analysis & Valuation

NYSE:IBTA • US4510511060

23.42 USD
+0.36 (+1.56%)
At close: Mar 13, 2026
23.42 USD
0 (0%)
After Hours: 3/13/2026, 4:39:35 PM

This IBTA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to IBTA. IBTA was compared to 91 industry peers in the Media industry. IBTA has an excellent financial health rating, but there are some minor concerns on its profitability. IBTA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

5

1. IBTA Profitability Analysis

1.1 Basic Checks

  • IBTA had positive earnings in the past year.
  • IBTA had a positive operating cash flow in the past year.
IBTA Yearly Net Income VS EBIT VS OCF VS FCFIBTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 2025 0 50M -50M 100M

1.2 Ratios

  • IBTA has a better Return On Assets (0.68%) than 74.73% of its industry peers.
  • With a decent Return On Equity value of 1.24%, IBTA is doing good in the industry, outperforming 72.53% of the companies in the same industry.
  • The Return On Invested Capital of IBTA (0.49%) is comparable to the rest of the industry.
  • IBTA had an Average Return On Invested Capital over the past 3 years of 13.82%. This is significantly above the industry average of 6.70%.
  • The last Return On Invested Capital (0.49%) for IBTA is well below the 3 year average (13.82%), which needs to be investigated, but indicates that IBTA had better years and this may not be a problem.
Industry RankSector Rank
ROA 0.68%
ROE 1.24%
ROIC 0.49%
ROA(3y)7.58%
ROA(5y)N/A
ROE(3y)50.92%
ROE(5y)N/A
ROIC(3y)13.82%
ROIC(5y)N/A
IBTA Yearly ROA, ROE, ROICIBTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 2025 0 50 -50 100 150

1.3 Margins

  • With a decent Profit Margin value of 1.04%, IBTA is doing good in the industry, outperforming 71.43% of the companies in the same industry.
  • IBTA has a Operating Margin (0.57%) which is in line with its industry peers.
  • The Gross Margin of IBTA (79.25%) is better than 94.51% of its industry peers.
  • In the last couple of years the Gross Margin of IBTA has remained more or less at the same level.
Industry RankSector Rank
OM 0.57%
PM (TTM) 1.04%
GM 79.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.49%
GM growth 5YN/A
IBTA Yearly Profit, Operating, Gross MarginsIBTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 2025 0 20 -20 40 60 80

7

2. IBTA Health Analysis

2.1 Basic Checks

  • IBTA has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • IBTA has less shares outstanding than it did 1 year ago.
  • IBTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IBTA Yearly Shares OutstandingIBTA Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2025 10M 20M 30M
IBTA Yearly Total Debt VS Total AssetsIBTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 2.17 indicates that IBTA is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • IBTA has a better Altman-Z score (2.17) than 74.73% of its industry peers.
  • IBTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 2.17
ROIC/WACC0.05
WACC8.85%
IBTA Yearly LT Debt VS Equity VS FCFIBTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2025 0 100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 1.96 indicates that IBTA should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.96, IBTA is in the better half of the industry, outperforming 72.53% of the companies in the same industry.
  • A Quick Ratio of 1.96 indicates that IBTA should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.96, IBTA is in the better half of the industry, outperforming 74.73% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.96
Quick Ratio 1.96
IBTA Yearly Current Assets VS Current LiabilitesIBTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 2025 100M 200M 300M 400M 500M

2

3. IBTA Growth Analysis

3.1 Past

  • The earnings per share for IBTA have decreased strongly by -21.05% in the last year.
  • The Revenue has decreased by -6.77% in the past year.
  • IBTA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.57% yearly.
EPS 1Y (TTM)-21.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-105.97%
Revenue 1Y (TTM)-6.77%
Revenue growth 3Y17.57%
Revenue growth 5YN/A
Sales Q2Q%-10.02%

3.2 Future

  • The Earnings Per Share is expected to decrease by -9.22% on average over the next years.
  • IBTA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.57% yearly.
EPS Next Y-497.32%
EPS Next 2Y-130.91%
EPS Next 3Y-9.22%
EPS Next 5YN/A
Revenue Next Year0.65%
Revenue Next 2Y5.3%
Revenue Next 3Y7.57%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
IBTA Yearly Revenue VS EstimatesIBTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M 400M
IBTA Yearly EPS VS EstimatesIBTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 0 0.2 -0.2 -0.4

2

4. IBTA Valuation Analysis

4.1 Price/Earnings Ratio

  • IBTA is valuated quite expensively with a Price/Earnings ratio of 156.13.
  • IBTA's Price/Earnings ratio is a bit cheaper when compared to the industry. IBTA is cheaper than 60.44% of the companies in the same industry.
  • IBTA is valuated expensively when we compare the Price/Earnings ratio to 25.71, which is the current average of the S&P500 Index.
  • IBTA is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 156.13
Fwd PE N/A
IBTA Price Earnings VS Forward Price EarningsIBTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, IBTA is valued a bit more expensive than the industry average as 61.54% of the companies are valued more cheaply.
  • Based on the Price/Free Cash Flow ratio, IBTA is valued a bit cheaper than 73.63% of the companies in the same industry.
Industry RankSector Rank
P/FCF 9.35
EV/EBITDA 36.47
IBTA Per share dataIBTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • A cheap valuation may be justified as IBTA's earnings are expected to decrease with -9.22% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-130.91%
EPS Next 3Y-9.22%

0

5. IBTA Dividend Analysis

5.1 Amount

  • No dividends for IBTA!.
Industry RankSector Rank
Dividend Yield 0%

IBTA Fundamentals: All Metrics, Ratios and Statistics

IBOTTA INC-CL A

NYSE:IBTA (3/13/2026, 4:39:35 PM)

After market: 23.42 0 (0%)

23.42

+0.36 (+1.56%)

Chartmill FA Rating
GICS IndustryGroupMedia & Entertainment
GICS IndustryMedia
Earnings (Last)02-25
Earnings (Next)05-18
Inst Owners53.23%
Inst Owner Change-17.21%
Ins Owners16.23%
Ins Owner Change8.98%
Market Cap570.28M
Revenue(TTM)342.39M
Net Income(TTM)3.58M
Analysts51.43
Price Target28.56 (21.95%)
Short Float %40.33%
Short Ratio10.73
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)660.91%
Min EPS beat(2)-292.16%
Max EPS beat(2)1613.97%
EPS beat(4)2
Avg EPS beat(4)393.53%
Min EPS beat(4)-292.16%
Max EPS beat(4)1613.97%
EPS beat(8)4
Avg EPS beat(8)200.98%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1.97%
Min Revenue beat(2)-0.34%
Max Revenue beat(2)4.28%
Revenue beat(4)1
Avg Revenue beat(4)-0.81%
Min Revenue beat(4)-6.83%
Max Revenue beat(4)4.28%
Revenue beat(8)3
Avg Revenue beat(8)-0.93%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.01%
EPS NQ rev (1m)-25.61%
EPS NQ rev (3m)-42.06%
EPS NY rev (1m)-51.11%
EPS NY rev (3m)-233.88%
Revenue NQ rev (1m)7.63%
Revenue NQ rev (3m)7.63%
Revenue NY rev (1m)5.18%
Revenue NY rev (3m)5.12%
Valuation
Industry RankSector Rank
PE 156.13
Fwd PE N/A
P/S 1.67
P/FCF 9.35
P/OCF 5.99
P/B 1.98
P/tB 1.98
EV/EBITDA 36.47
EPS(TTM)0.15
EY0.64%
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)2.5
FCFY10.69%
OCF(TTM)3.91
OCFY16.71%
SpS14.06
BVpS11.81
TBVpS11.81
PEG (NY)N/A
PEG (5Y)N/A
Graham Number6.31
Profitability
Industry RankSector Rank
ROA 0.68%
ROE 1.24%
ROCE 0.62%
ROIC 0.49%
ROICexc 1.18%
ROICexgc 1.18%
OM 0.57%
PM (TTM) 1.04%
GM 79.25%
FCFM 17.81%
ROA(3y)7.58%
ROA(5y)N/A
ROE(3y)50.92%
ROE(5y)N/A
ROIC(3y)13.82%
ROIC(5y)N/A
ROICexc(3y)31.21%
ROICexc(5y)N/A
ROICexgc(3y)31.49%
ROICexgc(5y)N/A
ROCE(3y)17.49%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.49%
GM growth 5YN/A
F-Score6
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 412.3%
Cap/Sales 10.02%
Interest Coverage 7.93
Cash Conversion 926.88%
Profit Quality 1705.48%
Current Ratio 1.96
Quick Ratio 1.96
Altman-Z 2.17
F-Score6
WACC8.85%
ROIC/WACC0.05
Cap/Depr(3y)220.67%
Cap/Depr(5y)N/A
Cap/Sales(3y)5.12%
Cap/Sales(5y)N/A
Profit Quality(3y)632.43%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-105.97%
EPS Next Y-497.32%
EPS Next 2Y-130.91%
EPS Next 3Y-9.22%
EPS Next 5YN/A
Revenue 1Y (TTM)-6.77%
Revenue growth 3Y17.57%
Revenue growth 5YN/A
Sales Q2Q%-10.02%
Revenue Next Year0.65%
Revenue Next 2Y5.3%
Revenue Next 3Y7.57%
Revenue Next 5YN/A
EBIT growth 1Y-92.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1624.74%
EBIT Next 3Y212.58%
EBIT Next 5YN/A
FCF growth 1Y-42.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.81%
OCF growth 3YN/A
OCF growth 5YN/A

IBOTTA INC-CL A / IBTA FAQ

What is the ChartMill fundamental rating of IBOTTA INC-CL A (IBTA) stock?

ChartMill assigns a fundamental rating of 4 / 10 to IBTA.


Can you provide the valuation status for IBOTTA INC-CL A?

ChartMill assigns a valuation rating of 2 / 10 to IBOTTA INC-CL A (IBTA). This can be considered as Overvalued.


What is the profitability of IBTA stock?

IBOTTA INC-CL A (IBTA) has a profitability rating of 5 / 10.


What are the PE and PB ratios of IBOTTA INC-CL A (IBTA) stock?

The Price/Earnings (PE) ratio for IBOTTA INC-CL A (IBTA) is 156.13 and the Price/Book (PB) ratio is 1.98.


Can you provide the financial health for IBTA stock?

The financial health rating of IBOTTA INC-CL A (IBTA) is 7 / 10.